Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13247942 | 0.88 | MAPK14 (0.41) | NPC1RAB9AKMT2AMAPK14GPR35 | |
| SCHEMBL13267945 | 0.85 | MAPK14 (0.39) | PDE4APDE4BPDE4CPDE4DNPC1 | |
| SCHEMBL2999895 | 0.85 | ALDH1A1 (0.41) | NPC1KMT2AMAPK14 | |
| SCHEMBL13247973 | 0.85 | MAPK14 (0.38) | NPC1KMT2AMAPK14BRAFKDR | |
| SCHEMBL2999891 | 0.85 | ALDH1A1 (0.41) | NPC1KMT2AMAPK14 | |
| SCHEMBL13247959 | 0.85 | ALDH1A1 (0.41) | NPC1KMT2AMAPK14 | |
| SCHEMBL2491849 | 0.84 | NPC1 (0.43) | PDE4APDE4BPDE4CPDE4DNPC1 | |
| SCHEMBL2516499 | 0.81 | CYP17A1 (0.43) | PDE4APDE4BPDE4CPDE4DNPC1 | |
| SCHEMBL3540920 | 0.79 | NPC1 (0.51) | PDE4APDE4BPDE4CPDE4DNPC1 | |
| SCHEMBL3540917 | 0.79 | NPC1 (0.51) | PDE4APDE4BPDE4CPDE4DNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379516-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010070343-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | GCGR, DGAT1, GPBAR1 | PDE4A 2862/4885PDE4B 2132/4885PDE4C 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.